Cosmax (A192820) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
23 Jun, 2026Executive summary
Consolidated sales reached 551.5 KRW bn in Q2 2024, up 15.1% YoY, with Korea leading growth and Southeast Asia outperforming guidance.
Leading global ODM specializing in cosmetics, with over 90% of sales from ODM contracts and a diversified client base in 100+ countries.
Operating profit rose 1.5% YoY to 46.7 KRW bn in Q2 2024, while net income increased 28.9% YoY to 35.3 KRW bn.
Maintains strong R&D focus, with 25% of employees in research roles and significant investment in innovation and sustainability.
Expanding into AI-driven personalized beauty platforms and renewable energy, with new business lines showing early revenue and growth potential.
Financial highlights
Q2 2024 gross profit increased 35.0% YoY to 112.0 KRW bn, with a stable cost ratio at 79.7%.
2024 H1 consolidated revenue: ₩1,078.3 billion, down from ₩1,777.5 billion in 2023 H1.
Operating income for H1 2024: ₩92.2 billion; net income: ₩54.9 billion.
Cash and equivalents at period end: ₩307.7 billion; total assets: ₩1,883.1 billion.
SG&A expenses rose 76.8% YoY in Q2 2024, impacting operating leverage.
Outlook and guidance
Southeast Asia exceeded annual guidance, driven by strong category growth and favorable business conditions.
Continued focus on global expansion, digital transformation, and personalized beauty solutions.
Plans for further investment in AI, platform development, and renewable energy to drive future growth.
Anticipates ongoing market volatility but expects growth in online and personalized product segments.
Latest events from Cosmax
- Q1 2025 revenue and operating profit grew, but net profit fell due to one-off and non-operating losses.A192820
Q1 202523 Jun 2026 - H1 2025 revenue hit KRW 1,212.1B, with net profit impacted by non-operating expenses.A192820
Q2 202523 Jun 2026 - Revenue up 1.0% YoY, but profit declined on one-off costs; R&D and ESG efforts remain strong.A192820
Q3 202523 Jun 2026 - Q1 2026 revenue up 15.9% YoY and net profit up 312.1%, driven by Korea and China growth.A192820
Q1 202631 May 2026 - Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.A192820
Q3 202420 Feb 2026 - Record Q4 profit growth driven by Korea and Southeast Asia, with net profit turning positive.A192820
Q4 202420 Feb 2026